Bobby has served as President and CEO of Tarsus Pharmaceuticals since co-founding the company in 2017. In that time, Tarsus has established a leading team and culture, and completed successful fundraising efforts through an IPO and global partnerships. Tarsus continues to advance its pipeline into clinical studies, including its lead product, TP-03, which is now in Phase 3 clinical trials and commercial planning.
Bobby also serves on the board and is Co-Chairman of Vibrato Medical, a medical device company developing a wearable treatment for peripheral arterial diseases, which has received NIH grant awards and generated first-in-human proof of concept clinical data. Previously, he was President and CMO of Metavention, a medical device company developing an interventional treatment for metabolic diseases, from inception through proof of concept clinical trials as well as Series A through Series C fundraising.
Bobby began his biotechnology career at Versant Ventures and Third Rock Ventures, where he was an investor and board observer in numerous life sciences companies. He also served on the board of the nonprofit organization Octane.
He trained as a physician scientist, completing his residency in internal medicine and serving as an attending hospitalist at Brigham and Women’s Hospital. He received an MD from Harvard Medical School (Harvard-MIT Heath Sciences and Technology), a PhD in chemistry from Oxford University as a Rhodes Scholar, and a BA in physics from Rice University. He is also an author of numerous patents and peer-reviewed publications.
What is Bobak R. Azamian's net worth?
The estimated net worth of Bobak R. Azamian is at least $1.34 million as of March 18th, 2024. Dr. Azamian owns 26,456 shares of Tarsus Pharmaceuticals stock worth more than $1,338,409 as of December 3rd. This net worth estimate does not reflect any other assets that Dr. Azamian may own. Learn More about Bobak R. Azamian's net worth.
How do I contact Bobak R. Azamian?
Has Bobak R. Azamian been buying or selling shares of Tarsus Pharmaceuticals?
Bobak R. Azamian has not been actively trading shares of Tarsus Pharmaceuticals during the last quarter. Most recently, Bobak R. Azamian sold 10,415 shares of the business's stock in a transaction on Monday, March 18th. The shares were sold at an average price of $30.60, for a transaction totalling $318,699.00. Following the completion of the sale, the chief executive officer now directly owns 26,456 shares of the company's stock, valued at $809,553.60. Learn More on Bobak R. Azamian's trading history.
Who are Tarsus Pharmaceuticals' active insiders?
Are insiders buying or selling shares of Tarsus Pharmaceuticals?
During the last year, Tarsus Pharmaceuticals insiders bought shares 1 times. They purchased a total of 1,000 shares worth more than $18,960.00. During the last year, insiders at the sold shares 7 times. They sold a total of 74,748 shares worth more than $1,767,177.60. The most recent insider tranaction occured on March, 18th when insider Aziz Mottiwala sold 4,766 shares worth more than $145,839.60. Insiders at Tarsus Pharmaceuticals own 8.3% of the company.
Learn More about insider trades at Tarsus Pharmaceuticals. Information on this page was last updated on 3/18/2024.
